Advertisement
Advertisement
SRZN
Surrozen, Inc. Common
23.36
USDSponsored
-0.61
-2.54%
Aug 25, 15:59 UTC -4
Closed
After-Market
23.25
-0.11
-0.47%
SRZN Earnings Reports
Positive Surprise Ratio
SRZN beat 10 of 20 last estimates.
50%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Surrozen, Inc. Common earnings per share and revenue
On Aug 06, 2026, SRZN reported earnings of -0.41 USD per share (EPS) for Q2 26, beating the estimate of -1.31 USD, resulting in a 68.79% surprise. Revenue reached 5.00 million, compared to an expected 476.60 thousand, with a 949.11% difference. The market reacted with a +18.39% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Surrozen, Inc. Common's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Surrozen, Inc. Common reported EPS of -$0.41, beating estimates by 68.79%, and revenue of $5.00M, 949.11% above expectations.
How did the market react to Surrozen, Inc. Common's Q2 2026 earnings?
The stock price moved up 18.39%, changed from $21.64 before the earnings release to $25.62 the day after.
When is Surrozen, Inc. Common expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Surrozen, Inc. Common's next earnings report?
Based on --
analysts, Surrozen, Inc. Common is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement